Insider Buying: Cyclo Therapeutics, Inc. (NASDAQ:CYTH) COO Buys $21,258.11 in Stock

Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Get Rating) COO Jeffrey Tate bought 29,941 shares of the stock in a transaction on Thursday, April 20th. The stock was purchased at an average cost of $0.71 per share, for a total transaction of $21,258.11. Following the acquisition, the chief operating officer now directly owns 62,101 shares of the […]

Related Keywords

Jeffrey Tate ,Charlese Rick Strattan ,Securities Exchange Commission ,Armistice Capital ,Maxim Group ,Exchange Commission ,Nasdaq ,Cyclo Therapeutics Company Profile ,Cyclo Therapeutics Inc ,Cyclo Therapeutics ,Get Rating ,Trappsol Cyclo ,Cyclo Therapeutics Daily ,Nasdaq Cyth ,Scyth ,Medical ,Insider Trading ,Nsider Trades ,Stocks ,